Jenkins, Gisli

Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report

Collard, H. R., Ryerson, C. J., Corte, T. J., Jenkins, G., Kondoh, Y., Lederer, D. J., Lee, J. S., Maher, T. M., Wells, A. U., Antoniou, K. M., et al. (2016) · American Journal of Respiratory and Critical Care Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 1,444

Control of confounding and reporting of results in causal inference studies. Guidance for authors from editors of respiratory, sleep, and critical care journals

Lederer, D. J., Bell, S. C., Branson, R. D., Chalmers, J. D., Marshall, R., Maslove, D. M., Ost, D. E., Punjabi, N. M., Schatz, M., Smyth, A. R., et al. (2019) · Annals of the American Thoracic Society

Advanced Causal Inference TechniquesStatistical Methods in Epidemiology

Cited by 715

COVID-19 and pulmonary fibrosis: a potential role for lung epithelial cells and fibroblasts

John, A. E., Joseph, C., Jenkins, G., & Tatler, A. L. (2021) · Immunological Reviews

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisCOVID-19 Clinical Research Studies

Cited by 219

Stretch-induced Activation of Transforming Growth Factor-β1 in Pulmonary Fibrosis

Froese, A. R., Shimbori, C., Bellaye, P.-S., Inman, M., Obex, S., Fatima, S., Jenkins, G., Gauldie, J., Ask, K., & Kolb, M. (2016) · American Journal of Respiratory and Critical Care Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisTGF-β signaling in diseases

Cited by 214

Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?

Wolters, P. J., Blackwell, T. S., Eickelberg, O., Loyd, J. E., Kaminski, N., Jenkins, G., Maher, T. M., Molina-Molina, M., Noble, P. W., Raghu, G., et al. (2018) · The Lancet Respiratory Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisOccupational and environmental lung diseases

Cited by 196

A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis

Chioccioli, M., Roy, S., Newell, R., Pestano, L., Dickinson, B., Rigby, K., Herazo-Maya, J., Jenkins, G., Ian, S., Saini, G., et al. (2022) · eBioMedicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisMicroRNA in disease regulation

Cited by 129

αvβ6 integrin may be a potential prognostic biomarker in interstitial lung disease

Saini, G., Porte, J., Weinreb, P. H., Violette, S. M., Wallace, W. A., McKeever, T. M., & Jenkins, G. (2015) · European Respiratory Journal

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisTransplantation: Methods and Outcomes

Cited by 106

Late Breaking Abstract - Safety, tolerability and antifibrotic activity of bexotegrast: Phase 2a INTEGRIS-IPF study (NCT04396756)

Wuyts, W. A., Valenzuela, C., Jenkins, G., Goldin, J. G., Kim, G. H. J., Jurek, M., Turner, S., Decaris, M., Barnes, C. N., Lefebvre, É., et al. (2023) · Idiopathic interstitial pneumonias

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments

Cited by 7